Blood-ISBT 2025

October 26-29, 2025
Perth, Australia

Blood 2025 and the 36th Regional Congress of the ISBT

Explore more Hematology congress materials

Results(3)

Hematology

Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensus

Author(s): Mehta P., Martínez-Roca A., Cahalin, P. et al.

Impact of dose ratio variation on the comparative effectiveness of daunorubicin- and idarubicin-based regimens in acute myeloid leukaemia: a meta-regression analysis

Author(s): Franz A., Fong C. Y., de Andrés-Nogales et al.

V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia

Author(s): Thomas W. LeBlanc, Catherine Lai, Amir Ali et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.